Real-World Impact of Anti-CGRP mAbs on Migraine Relief

Research Summary

A recent study published in Neurology and Therapy explored the real-world use of anti-CGRP monoclonal antibodies (mAbs) for migraine prevention within a large U.S. healthcare network. Among 4683 eligible migraine patients, 484 completed a survey on their experiences. Key findings include that 90% of participants maintained their treatment for at least 2 months, 74% for 6 months, and 55% for 12 months. Current users of anti-CGRP mAbs reported greater reductions in headache frequency (62% vs. 18%), improved functionality (62% vs. 18%), and better quality of life (62% vs. 18%) compared to past users, highlighting significant patient satisfaction and persistence.

Study Details

📄 Title: Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

👥 Research Team: Buse DC et al.

📚 Published In: Neurol Ther

📅 Publication Date: 2025 Dec 17

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.